Article

Drug Label Overload

Author(s):

'Over-warning' or necessary adverse drug event information?

Prescription drug labels serve as a source of information for healthcare providers as well as consumers. Researchers from Indiana University School of Medicine in Indianapolis, Indiana recently reviewed the adverse drug warnings on the labels of 5,000 prescription drugs. The number of adverse drug event warnings ranged from 0 to 525 per label (mean = 70).

More warnings, on average, appeared on the labels of the 200 most commonly prescribed drugs, and newer medications (those approved in the past decade) had significantly higher numbers of adverse events per label than older drugs. The researchers noted that the large amount of adverse drug warning information, which they referred to as “over-warning,” could result in information overload.

I have to agree; a large amount of adverse drug warning information on drug labels may actually be harmful rather than helpful. Busy clinicians do not have the time, nor the patience, to sort through dozens of potential adverse events that appear on drug labels. Every reported event appears on drug labels, and I often wonder if the drug caused or contributed to some of the reported adverse events, or if they were coincidental occurrences. In addition, we need to be knowledgeable about drug interactions since most of our patients are taking two or more prescription drugs. Fortunately there are several online tools that identify potential drug interactions; just type “drug interaction checker” into a search engine to see multiple options for checking for drug interactions.

Reference

Duke J, et al "A quantitative analysis of adverse events and 'overwarning' in drug labeling" Arch Intern Med 2011; 171 (10): 944-946. Arch Intern Med

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center